The value of PET or PET/CT with $^{18}$F-FDG for the staging of penile cancer has yet to be determined. The objective of this study was to investigate the pattern of $^{18}$F-FDG uptake in the primary malignancy and its metastases and to determine the diagnostic value of $^{18}$F-FDG PET/CT in the staging and restaging of penile cancer. **Methods:** Thirteen patients (mean ± SD age, 64 ± 14.0 y) with suspected penile cancer or suspected recurrent disease were examined with a Gemini PET/CT system (200 MBq of $^{18}$F-FDG). The reference standard was based on histopathologic findings obtained at biopsy or during surgery. **Results:** Both the primary tumor and regional lymph node metastases exhibited a pattern of $^{18}$F-FDG uptake typical for malignancy. Sensitivity in the detection of primary lesions was 75% (6/8), and specificity was 75% (3/4). On a per-patient basis, sensitivity in the detection of lymph node metastases was 80% (4/5), and specificity was 100% (8/8). On a nodal-group basis, PET/CT showed a sensitivity of 69% (8/9) in the detection of metastases in the superficial inguinal lymph node basins and a sensitivity of 100% (7/7) in the deep inguinal and obturator lymph node basins. The mean ± SD maximum standardized uptake value for the 8 primary lesions was 5.3 ± 3.7, and that for the 16 lymph node metastases was 4.6 ± 2.0. **Conclusion:** According to our results, the main indication for $^{18}$F-FDG PET in the primary staging or follow-up of penile cancer patients may be the prognostically crucial search for lymph node metastases. With the use of a PET/CT unit, the additional information provided by CT may be especially useful for planning surgery. Implementing $^{18}$F-FDG PET and PET/CT in future staging algorithms may lead to a more precise and stage-appropriate therapeutic strategy. Furthermore, invasive procedures with high morbidity rate, such as sentinel lymph node biopsy (SLNB) or general lymphadenectomy, are associated with a high morbidity rate. Obviously, patients would benefit from a diagnostic protocol that is noninvasive yet robust and that is able to detect regional lymph node metastases and possible distant metastases with high degrees of sensitivity and specificity.

**Key Words:** PET/CT; $^{18}$F-FDG; penile cancer


In Europe and the United States, malignant lesions of the penis, measured as a percentage of all types of cancer in males, amount to only 0.4%–0.6%, and these tumors are responsible for less than 1%–2% of all deaths (1,2). In comparison, they are much more common in developing countries, such as Puerto Rico, Uganda, and even China. In these countries, carcinoma of the penis represents up to 10%–22% of all malignancies in males (1).

The overall prognosis of penile carcinoma depends on the involvement of regional lymph nodes (2,3). To date, noninvasive N and M staging has depended on ultrasound, CT, and MRI. These imaging methods, however, have not proven sufficiently robust in the detection of metastases (1). In many cases, therefore, patients have undergone invasive procedures, such as sentinel lymph node biopsy (SLNB) or general lymphadenectomy, a procedure that is associated with a high morbidity rate. Obviously, patients would benefit from a diagnostic protocol that is noninvasive yet robust and that is able to detect regional lymph node metastases and possible distant metastases with high degrees of sensitivity and specificity.

PET has been shown, in principle, to be a suitable complementary procedure to conventional morphologic imaging methods for the TNM staging of several malignant entities (4). A PET/CT scanner recently was introduced to partially address the poor degree of anatomic resolution of PET by adding high-resolution anatomic imaging provided by CT. This innovative imaging technique, with the radiopharmaceutical $^{18}$F-FDG, could prove useful in the noninvasive imaging of penile cancer.

It is known that squamous cell carcinomas often exhibit a high level of $^{18}$F-FDG uptake in relation to normal tissue and, hence, may be amenable to diagnosis by PET (5). In over 95% of cases, penile carcinoma is found histologically to be squamous cell carcinoma (1). The objective of the present prospective clinical study was to investigate for the first time whether penile carcinoma exhibits a sufficiently high level of $^{18}$F-FDG uptake to be amenable to diagnosis by means of PET. In addition, the study examined the performance of $^{18}$F-FDG PET/CT in the TNM staging of this malignancy, including the prognostically crucial determination of patients’ lymph node status.

**MATERIALS AND METHODS**

**Patient Collective**

Included in the present study were 13 patients with a mean ± SD age of 64 ± 14.0 y (range, 25–81 y). For 10 patients, examinations were conducted on the basis of a high degree of suspicion of penile cancer after clinical inspection. The 3 remaining patients included in the study presented for follow-up after resection or...
partial amputation of the penis secondary to penile cancer. After
eamination by palpation, inguinal lymph node metastases were
pected in 1 of these patients. In the second patient, a previously
formed MRI examination aroused suspicion of local disease
urrence at the site of resection. In the third patient, complete
section of a T1-stage tumor was doubtful on the basis of his-
opathologic examination. One other patient was examined a sec-
time by 18F-FDG PET/CT because of clinical suspicion of
local recurrence of lymph node metastases after radical bilateral
ymphadenectomy. Both PET/CT scans were included in the data
alysis. The human study was approved by the Institutional
iew Board of the University of Munich and was performed in
accordance with the ethical standards described in the Declaration
of Helsinki. Informed consent of the patients was obtained before
clusion in the study.

18F-FDG PET/CT
18F-FDG PET/CT was performed for whole-body staging. Pa-
tients fasted for at least 6 h before the examination to maintain
sium glucose concentrations below 120 mg/dL. All examinations
ere performed with a Gemini PET/CT system (Philips), consist-
ing of a dedicated germanium oxyorthosilicate full-ring PET
anner and a dual-slice helical CT scanner. After intravenous injection
of 18F-FDG (200 MBq), patients received 20 mg of furosemide to
accelerate renal 18F-FDG elimination and 20 mg of butylscopol-
amine bromide to decrease intestinal 18F-FDG uptake (6). All
patients underwent placement of an indwelling urinary catheter to
 prevent collection of urine, which could compromise visualization
of the lower pelvis. The catheter was fixed with adhesive tape, so
that the penis was oriented in the upright position. At 60 min after
the application of the tracer, low-dose CT (20 mA, 140 kV, 512
matrix) covering the area from the base of the skull to the
proximal thighs was performed. According to our standard clinical
protocol, this scan was used for the purpose of attenuation correc-
tion, thus avoiding possible artifacts related to intravenous contrast
medium. Thereafter, emission measurement was conducted cau-
docranially in the 3-dimensional mode with a 144 × 144 matrix.
Emission scan time per bed position was 3 min; 10 bed positions
(field of view, 155 mm) were acquired. After the emission scan, a
diagnostic CT scan of the thorax, abdomen, and pelvis was per-
formed after automated intravenous injection of 120 mL (2.5
mL/s) of iodine-containing contrast medium (Ultrascan 300; Scher-
ing). Scan delay after injection was 50 s to depict the venous
phase. Diagnostic dual-slice CT with an axial field of view of 600
mm and a matrix of 512 × 512 was performed in the spiral mode
under continuous acquisition at 120 kV and 145 mA (slice thick-
ess of 5.0 mm, increment of 2.5 mm/s, rotation time of 0.5 s, and
pitch index of 1). The average total PET/CT examination time was
40 min.

Data Reconstruction, Standardized Uptake Value (SUV)
Measurement, and Statistical Analysis
After scatter and decay correction, PET data were reconstructed
iteratively with and without attenuation correction and reoriented
in axial, sagittal, and coronal slices. A fully 3-dimensional re-
construction algorithm based on the row action maximum-likelihood
algorithm was used with PETView software (Philips) (7,8). Ac-
gording to our routine protocol, 2 iterations and a relaxation
parameter of 0.0035 were used. In addition, multiplanar recon-
structions of the CT data were performed. Manually defined
polyomorph regions of interest were drawn on the attenuation-
corrected PET image throughout all axial planes in which a sus-
pected lesion could be delineated, tightly including the focus of
increased 18F-FDG uptake. For this procedure and for qualitative
image analysis, Syntegra software (Philips) was used. The maxi-
mum SUV (SUV max) was documented in an Excel database (Mi-
crosoft) for each lesion. The program SPSS version 11.0 (SPSS
Inc.) was used for statistical treatment of the data. Means are
presented with 1 SD. The Mann–Whitney U test for 2 independent
samples was performed to compare the SUV max of grade 2 and the
SUV max of grade 3 primary tumors. The maximum diameter of all
lymph node metastases was assessed by CT, and lesions smaller
than 2.5 cm were compared with their corresponding SUV max by
linear regression analysis. In addition, a 2-tailed test for signifi-
cance of the Pearson correlation coefficient was performed. Two-
tailed P values of <0.05 were considered significant.

Reference Standard
The reference standard used in this study is based on histopatho-
logic findings obtained at biopsy or during surgery. Surgical pro-
cedures included excision of the primary malignancy, partial am-
putation of the penis, and radical bilateral lymphadenectomy. The
1997 TNM staging system was used to determine the pathologic
stage of the primary tumor and its metastases (9). Intraoperative
resection specimens were sent for frozen-section examination and
afterward for final histopathologic examination, consisting of rou-
tine paraffin-section examination, hematoxylin–eosin staining, and
immunohistochemical staining. In 3 patients with histopathologi-
cally confirmed T1 G2 primary malignancies, lymphadenectomy
was not performed because of tumor stage and grade. After sur-
 gical resection of the primary tumor, these patients were monitored
for a follow-up period of at least 6 mo. During that interval, MRI
of the pelvis, ultrasonography of the inguinal region, and clinical
examinations were performed, including manual palpation and
tumor marker testing for squamous cell carcinoma antigen. The
findings of 18F-FDG PET/CT were used as a guide during bilateral
lymphadenectomy.

Study Design
All examinations were performed prospectively and interpreted
by investigators aware of the patient’s underlying disease but
unaware of the results of other diagnostic imaging methods or any
other clinical information. Initially, PET images were read inde-
pendently from CT images by a certified nuclear medicine physi-
cian with over 10 y of PET experience. Evaluation of PET images
included both attenuation-corrected and noncorrected images. The
interpretation of a lesion as benign or malignant was based pri-
arily on a visual analysis. SUV max served solely as guidance. After
the PET reviews, fused PET/CT images were evaluated in
consensus with a radiologist with over 3 y of CT experience.
Lesions classified as malignant by PET maintained a malignant
status when the corresponding CT image revealed a morphologic
correlate, for example, a lymph node abnormality. Any abnormal-
ities seen on CT without corresponding increased 18F-FDG uptake
were interpreted as nonmalignant. We did not aim to compare the
diagnostic efficacy of PET/CT with that of stand-alone PET or CT.
Therefore, the results presented are based primarily on the infor-
mation provided by PET, and CT was used mainly for exact
anatomic localization. For this purpose, precise image fusion, as
provided by the PET/CT system, was of great importance.
RESULTS

Primary Lesions

All primary malignancies were squamous cell carcinomas located on the glans penis. In 8 of 13 patients, penile cancer was confirmed by histopathologic examination. Six of these 8 cases showed intense \(^{18}\)F-FDG uptake and were diagnosed as true-positive cases by \(^{18}\)F-FDG PET/CT (Fig. 1). Five of these 8 patients had grade 2 lesions, whereas 3 of 8 had grade 3 lesions. The maximum diameter of primary lesions, as assessed during surgery, ranged from <0.5 cm to 3.5 cm. PET/CT results were interpreted as false negative in 2 of 8 patients. In 1 of these 2 patients, a T1 G2 tumor with a maximum diameter of 0.5 cm was missed. The second patient was referred to our hospital for reexcision after incomplete resection of a T1 G2 tumor at another clinic. Retrospectively, in both cases, a discrete increase in \(^{18}\)F-FDG uptake corresponding to the lesion could be delineated. However, the \(^{18}\)F-FDG uptake pattern was falsely interpreted as nonmalignant during image analysis. In 1 of 13 patients, histologic examination revealed carcinoma in situ (CIS). The tumor did not penetrate the basilar membrane, and PET/CT revealed no pathologic findings. Histopathologic examination revealed no signs of malignancy in 4 of 13 patients. PET/CT results were interpreted as false positive in 1 of these 4 patients, who showed slight \(^{18}\)F-FDG uptake at the glans penis, with an SUV\(_{\text{max}}\) of 1.4. Because of its focal character, this lesion was interpreted as malignant. However, after histopathologic examination, the lesion was found to be caused by inflammatory changes attributable to Wegener’s disease. PET/CT results were interpreted as true negative in 3 of these 4 patients. One of these patients had partial necrosis of the glans penis caused by peripheral arterial occlusive disease resulting from diabetes mellitus. On clinical inspection, this lesion was mistaken for penile cancer. PET/CT showed no increased \(^{18}\)F-FDG uptake at the site of necrosis. In the other 2 patients, who had a history of partial amputation of the penis, \(^{18}\)F-FDG PET/CT showed no pathologic \(^{18}\)F-FDG uptake at the resection site, although MRI aroused suspicion of local recurrence in 1 patient. Biopsy, however, revealed no malignancy.

On the basis of our data for this selected patient population, \(^{18}\)F-FDG PET/CT showed a sensitivity of 75% (6/8) and a specificity of 75% (3/4) in the detection of primary lesions. CIS was not included in these calculations because malignancies at this stage are generally not detectable by either PET or conventional morphologic imaging techniques.

Metastases

In 5 of 13 patients, histopathologic examination revealed lymph node metastases, which were localized bilaterally in 2 patients. One of these patients underwent a second PET/CT scan after radical bilateral lymphadenectomy. He developed recurrence of the metastatic spread in the right inguinal and iliac region. Both PET/CT examinations of this patient were included in the data analysis. A total of 16 lymph node metastases were verified by histopathologic examination in these 5 patients. Nine metastatic lesions were located in the superficial inguinal region, and another 5 lymph node metastases were found in the deep inguinal lymph node basins. Two more lesions were located in the obturator region. PET/CT results were interpreted as true positive for all lymph node metastases located in the deep inguinal lymph node basins. Two more lesions were located in the obturator region. PET/CT results were interpreted as true positive for all lymph node metastases located in the deep inguinal lymph node basins, and there was a single false-negative finding in 1 of the 9 superficial inguinal lesions. In total, PET/CT identified 15 of 16 lymph node metastases as true positive.

The majority of the metastatic lesions showed intense \(^{18}\)F-FDG uptake (Fig. 2). All of the foci rated as malignant by PET corresponded to lymph nodes on CT. Three metastatic lymph nodes were ≤1 cm in diameter. The diameter of the single false-negative lesion was 1.8 cm. Despite the pathologic size on CT, the lesion was interpreted as nonmalignant because of the rather discrete \(^{18}\)F-FDG uptake seen on PET, with an SUV\(_{\text{max}}\) of 1.1. Intraoperative frozen sections showed no malignancy. However, appropriate histopathologic examination of this lymph node revealed a micrometastasis. This patient had no other metastatic lesions and therefore was inaccurately categorized by PET.

In 8 of 13 patients, neither clinical findings nor diagnostic imaging procedures aroused suspicion of lymph node metastases. In 3 of these 8 patients, lymph node metastases could be ruled out with respect to the primary lesion (partial necrosis, Wegener’s disease, and CIS). In another 2 patients, a radical bilateral lymphadenectomy was performed and revealed no malignancy. The remaining 3 patients were monitored for a follow-up period of at least 6 mo. PET/CT results were interpreted as true negative in all 8 patients, and there were no false-positive findings.

FIGURE 1. Axial (left) and sagittal (right) PET (top) and PET/CT (bottom) images of 66-y-old man with cancer at glans penis (arrows). \(^{18}\)F-FDG uptake is intense. Histopathologic examination revealed T2 G3 tumor with maximum diameter of approximately 3 cm.
In summary, \(^{18}\)F-FDG PET/CT results were interpreted as true positive in 15 of 16 lymph node metastases, and there was only 1 false-negative finding corresponding to a micro-metastasis. As this was the single metastatic lesion in this patient, sensitivity in the detection of lymph node metastases was 80\% (4/5) on a per-patient basis. On a nodal-group basis, PET/CT showed a sensitivity of 89\% (8/9) in the detection of superficial inguinal lesions, whereas all lymph node metastases located in the deep inguinal and obturator lymph node basins were identified as true positive, resulting in a sensitivity of 100\% (7/7). The sensitivity of PET/CT on a per-lesion basis was 94\% (15/16). The results for all 8 patients without metastatic spread were interpreted as true negative; the specificity of PET/CT in the detection of lymph node metastases therefore was 100\% (8/8) on a per-patient basis.

**SUVs**

\(^{18}\)F-FDG uptake in histopathologically proven primary malignancies and lymph node metastases was markedly high. The mean ± SD SUV\(_{\text{max}}\) of the 8 histopathologically proven malignant lesions (CIS was not included) was 5.3 ± 3.7, with a range of 1.9 to 12.1. When grade 2 tumors are compared with grade 3 tumors, a tendency is visible: grade 3 lesions show higher \(^{18}\)F-FDG uptake (mean ± SD SUV\(_{\text{max}}\), 7.9 ± 3.9) than grade 2 tumors (mean ± SD SUV\(_{\text{max}}\), 3.7 ± 2.9). However, it may be speculated that because of the small sample size, this difference was not significant (\(P = 0.143\)). The SUV\(_{\text{max}}\)s of benign lesions (necrosis and Wegener’s disease) and of regions of interest drawn around the distal part of the penis after partial amputation were ±1.5 (Fig. 3). With regard to lymph node metastases, the mean ± SD SUV\(_{\text{max}}\) of the 16 lesions was 4.6 ± 2.0, with a range of 1.1 to 7.6. In 3 lymph node metastases, the SUV\(_{\text{max}}\) was lower than 3.0. In 1 of these cases, a lesion with an SUV\(_{\text{max}}\) of 1.1 was found to be a micrometastasis. In the other 2 cases, the lymph node metastases had maximum diameters, as assessed by CT, of less than 1 cm, with SUV\(_{\text{max}}\)s of 1.3 and 2.8. This effect is known to occur with SUV quantification of smaller lesions because of partial-volume effects caused by the limited spatial resolution of PET.

**DISCUSSION**

The diagnosis of penile carcinoma is most often established by biopsy of the visually inspected area of suspicion. With respect to lymphogenous metastasis, Solsona et al. have reported a correlation between increasing stage and grade and the occurrence of lymph node metastases (10). We have been able to confirm this observation in our own patient collective. Of 5 patients with confirmed lymphogenous metastasis, 4 patients were staged at T2 G3 and only 1 was staged at T1 G2. Distant metastases occur in less than 10\% of cases and are generally associated with regional lymph node involvement (2).

Despite adequate treatment, which is based primarily on surgical procedures, further progression of the disease cannot be prevented in up to 40\% of patients (11). The overall prognosis of penile carcinoma depends on both T staging and grading of the primary tumor, together with the presence or absence of lymphogenous metastasis (3,12). The noninvasive evaluation of possible lymph node involvement begins with palpation and is supplemented with cross-sectional imaging techniques, such as ultrasound, CT, and MRI (13). Ultrasound is considered unreliable with regard to N staging (14). The other cross-sectional radiologic imaging techniques also have proven disappointing in evaluating patients for possible regional lymph node involvement (1). For example, Lont et al. described frequent false-positive findings with CT and MRI (15). One reason for this phe-
nomenon is that lymph nodes undergo reactive changes secondary to malignant disease in the penis (3). Furthermore, even under physiologic conditions, the diameter of lymph nodes in the inguinal region can exceed 2 cm in the absence of malignancy. According to Algaba et al., 20%–96% of patients have palpable lymph nodes at the time of first diagnosis, although actual lymphogenous metastasis is present in only 17%–45% of these patients (14). An invasive option for assessing lymphogenous metastasis is SLNB after peritumoral injection of nanocolloid particles that are marked with $^{99m}$Tc. For some tumor entities, such as mammary cancer, this procedure is known to have high accuracy (16). Tanis et al., however, reported a comparatively low overall sensitivity of 78% in penile cancer (17). Although noninvasive imaging techniques generally should not serve as a replacement for SLNB, this invasive method is not yet considered a standard procedure in the examination of penile cancer patients, as is the case with several other malignancies. The unsatisfactory accuracy of currently available diagnostic methods supports the demand for general, preventive lymphadenectomy (3). Some authors consider this approach to be indicated only for G3 tumors in stages T2–T4 (18). General bilateral lymphadenectomy is associated with a high morbidity rate of 30%–50% (14).

$^{18}$F-FDG PET has been shown to be particularly useful in assessing lymph node status (4). A disadvantage of the method is its low spatial resolution, which often precludes exact anatomic localization of pathologic changes. These problems, however, can be partially compensated by recently introduced PET/CT scanners. Preliminary studies have shown that PET/CT has, in some cases, resulted in diagnostic accuracy higher than that of the individual techniques (19–22). The objective of the present study was to investigate for the first time the basic suitability of $^{18}$F-FDG PET/CT in the diagnosis of penile carcinoma. At present, there are no systematic studies of larger collectives by PET or PET/CT for TNM staging or diagnosis of recurrent disease in patients with penile carcinoma. To our knowledge, the international literature includes only 3 cases that suggest increased $^{18}$F-FDG uptake in penile carcinoma. In a case report that focused primarily on a novel polychemotherapy regimen, Joerger et al. reported a metastatic lymph node that was discovered incidentally at follow-up and that showed increased $^{18}$F-FDG uptake (23). Ravizzini et al. also described a lesion with positive $^{18}$F-FDG uptake in a patient with penile carcinoma (24). Finally, Langen et al. reported a coincidentally discovered metastatic inguinal lymph node that showed increased $^{18}$F-FDG uptake (25). In none of these studies was the efficacy of $^{18}$F-FDG PET in the diagnosis of penile carcinoma the primary focus.

Our findings in 13 patients show that both the primary tumor and regional lymph node metastases exhibit a pattern of $^{18}$F-FDG uptake typical for malignancy. In our selected patient population, $^{18}$F-FDG PET/CT showed a sensitivity of 75% (6/8) and a specificity of 75% (3/4) for the group of primary malignancies. With regard to the pattern of uptake of the primary tumor, there was a trend suggesting that the grade of the tumor exerts a certain influence over the intensity of $^{18}$F-FDG uptake. Because the primary tumor is very accessible to biopsy and because distant metastases are fairly rare and occur only in very advanced disease stages, the main indication, in our opinion, for $^{18}$F-FDG PET and PET/CT is in the area of N staging. For this purpose, we found a high sensitivity of 94% (15/16) on a per-lesion basis and no false-positive findings. PET/CT missed only 1 of 16 lesions, which was found to be a lymph node micrometastasis. On a nodal-group basis, the sensitivity of PET/CT was 89% (8/9) in the detection of metastases in the superficial inguinal lymph node basins. Furthermore, all lesions located in the deep inguinal and obturator lymph node basins were detected as true-positive lesions (7/7). Metastatic spread to the deep inguinal or obturator lymph node basins results in N3-stage disease (9).

Data provided by PET made it possible to assess the malignancy of lymph nodes independent from a system of classification that is oriented primarily on size, as is the case with CT and MRI. The use of PET/CT scanners may prove especially useful in preoperative therapy planning. The information provided by CT allows exact evaluation of the anatomic position of the lesion and neighboring structures. A further future area of application for $^{18}$F-FDG PET and PET/CT may be in follow-up.

As has been shown in our collective for 4 metastatic lymph nodes measuring 0.7–1.1 cm in diameter, even small lesions can be detected because of the usually intense pattern of tracer uptake in this type of malignant disease. One of these lesions exhibited a rather low SUV$_{\text{max}}$ of 1.3. At first, this metastatic lesion was incorrectly classified as nonmalignant by reading of the PET image because of discrete tracer uptake. However, on the basis of exact image fusion with CT, which revealed a lymph node with a diameter of 0.8 cm at this site, the status was changed to malignant during consensus reading (Fig. 4). The relatively low
SUV\textsubscript{max} of this lesion can be explained by a partial-volume effect. We accordingly found a significant positive correlation between SUV\textsubscript{max} and the maximum diameter of metastatic lymph nodes up to 2.5 cm in diameter (Pearson correlation coefficient, 0.75; \( P = 0.019 \)). As is well known, this effect can be minimized by determining scanner-specific calibration factors (26–28). In routine interpretation, however, it is usual to refer to the uncorrected and easily determined SUV\textsubscript{max}. Especially for small lesions, this value should be used only for guidance and should not be considered an absolute value.

Because of the low prevalence of this tumor entity, this study was based on a selected patient population, including both initial staging and restaging of patients. This heterogeneous patient group must be considered a limitation of this study. Another limitation may be the use of \(^{18}\text{F-FDG}\) PET/CT findings as a guide during bilateral lymphadenectomy. Although this approach ensured resection of all suspected lymph nodes, it also could have biased the underlying reference standard. One intrinsic limitation of \(^{18}\text{F-FDG}\) PET and PET/CT is the detection of micrometastases. Although the scanner-specific resolution of modern PET scanners is less than 1 cm for lesions with intense tracer uptake, the detection of smaller micrometastases is usually unsuccessful. In our collective, 1 micrometastasis represented the only false-negative finding in the N staging. Because the methodical approaches of SLNB and PET/CT are different, the application of SLNB parallel to PET/CT may reduce the risk of unrecognized micrometastasis. A combination of both methods may ensure a sufficiently high degree of diagnostic accuracy to dispense with general lymphadenectomy which, although practiced by some centers, is associated with a high morbidity. This scenario is especially possible in cases with low-grade disease and a low T stage.

**CONCLUSION**

In this selected patient group, the majority of primary malignancies as well as their metastases showed markedly increased \(^{18}\text{F-FDG}\) uptake. \(^{18}\text{F-FDG}\) PET/CT showed high sensitivity and specificity in the staging and restaging of penile cancer. Morphologic information provided by CT and the possibility of exact image fusion may prove especially useful for planning surgery. We therefore conclude that \(^{18}\text{F-FDG}\) PET/CT is of value in the staging of penile cancer. Implementation of PET and PET/CT in future staging algorithms may lead to an increase in diagnostic efficacy and consequently to more precise and stage-appropriate therapeutic regimens. Furthermore, the added diagnostic security provided by PET may help to decrease the need for invasive procedures with a high morbidity rate, such as general bilateral lymphadenectomy, which then may be avoided in cases with a low tumor stage or grade.

**REFERENCES**